Credit Agricole S A Biomarin Pharmaceutical Inc Transaction History

Credit Agricole S A

$18.2 Billion
Q2 2024

A detailed history of Credit Agricole S A transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Credit Agricole S A holds 5,440 shares of BMRN stock, worth $370,844. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,440

Previous 1,350 302.96%

Holding current value

$370,844

Previous $117,000 282.05%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$74.43 - $92.22 $304,418 - $377,179	4,090 Added 302.96%	5,440 $447,000
Q1 2024 May 14, 2024	SELL	$83.81 - $99.0 $838 - $990	-10 Reduced 0.74%	1,350 $117,000
Q4 2023 Feb 13, 2024	SELL	$76.22 - $98.51 $8,003 - $10,343	-105 Reduced 7.17%	1,360 $131,000
Q3 2023 Nov 14, 2023	SELL	$85.07 - $94.48 $19,651 - $21,824	-231 Reduced 13.62%	1,465 $129,000
Q2 2023 Jul 31, 2023	BUY	$86.68 - $100.3 $60,329 - $69,808	696 Added 69.6%	1,696 $147,000
Q3 2021 Nov 15, 2021	SELL	$74.77 - $85.47 $104,678 - $119,658	-1,400 Reduced 58.33%	1,000 $77,000
Q1 2021 May 17, 2021	BUY	$74.73 - $90.69 $89,676 - $108,828	1,200 Added 100.0%	2,400 $181,000
Q1 2019 May 14, 2019	BUY	$84.2 - $98.62 $16,840 - $19,724	200 Added 20.0%	1,200 $107,000
Q2 2018 Aug 10, 2018	BUY	$76.01 - $99.03 $76,010 - $99,030	1,000 New	1,000 $94,000
Q4 2017 Feb 13, 2018	SELL	$80.76 - $95.13 $13.7 Million - $16.1 Million	-169,520 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$80.6 - $94.95 $2.96 Million - $3.49 Million	36,712 Added 27.64%	169,520 $15.8 Million
Q2 2017 Aug 14, 2017	BUY	N/A	132,808	132,808 $12.1 Million

Others Institutions Holding BMRN

# of Institutions

631

Shares Held

185M

Call Options Held

1.63M

Put Options Held

1.2M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.7B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Agricole S A, based on Form 13F filings with the SEC.

News

Stay updated on Credit Agricole S A with notifications on news.

Account

Credit Agricole S A Biomarin Pharmaceutical Inc Transaction History